Therapeutic efficacy of upadacitinib in refractory juvenile idiopathic arthritis: a case report
Frontiers in Pediatrics · 10.07.2026 · 14
DOI: 10.3389/fped.2026.1869089 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Pediatrics, online erschienen am 10.07.2026. Verfasst von Ningning Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Central Hospital of Dalian University of Technology, Dalian, China. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Juvenile idiopathic arthritis (JIA) remains a clinical challenge when conventional and biological therapies fail. Case presentation This report describes a case of highly refractory JIA and evaluates the efficacy of the Janus kinase (JAK) inhibitor upadacitinib, providing a potential therapeutic reference for difficult-to-treat pediatric autoimmune diseases. A 16-year-old female presented with a 3-year history of polyarticular swelling and pain that worsened over 1 month. Physical examination revealed extensive tenderness in the small joints of the hands, feet, and knees. Functional impairment was noted in the shoulder joints (restricted abduction and lifting) and wrist joints (limited flexion and extension). Laboratory results showed an erythrocyte sedimentation rate of 26 mm/h and a C-reactive protein level of 18.39 mg/L. Musculoskeletal ultrasound indicated grade 1 synovitis with effusion in the bilateral metacarpophalangeal, proximal interphalangeal, and distal interphalangeal joints, as well as both wrist joints. Effusion was also observed in the suprapatellar bursae of both knees. The patient's condition was classified as refractory, with prior failure of multiple lines of therapy, including conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), various biologic DMARDs (bDMARDs) (such as TNF, IL-6, and IL-1 inhibitors), and targeted synthetic DMARDs, such as tofacitinib. Following initiation of upadacitinib, the patient achieved marked clinical remission and improved joint mobility.
Conclusions
Upadacitinib demonstrated potent efficacy in a pediatric patient with JIA who was nonresponsive to multiple bDMARDs and tofacitinib. These findings suggest that upadacitinib may be a viable salvage therapy for refractory JIA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Central Hospital of Dalian University of Technology, Dalian, China.
Zitieren
APA
Li, N., Zhang, H., & Dai, B. (2026). Therapeutic efficacy of upadacitinib in refractory juvenile idiopathic arthritis: a case report. Frontiers in Pediatrics, 14. https://doi.org/10.3389/fped.2026.1869089
Vancouver
Li N, Zhang H, Dai B. Therapeutic efficacy of upadacitinib in refractory juvenile idiopathic arthritis: a case report. Frontiers in Pediatrics. 2026;14. doi:10.3389/fped.2026.1869089
BibTeX
@article{Li2026,
author = {Li, Ningning and Zhang, Hao and Dai, Bingbing},
title = {Therapeutic efficacy of upadacitinib in refractory juvenile idiopathic arthritis: a case report},
journal = {Frontiers in Pediatrics},
year = {2026},
volume = {14},
doi = {10.3389/fped.2026.1869089}
}
EUVIMED